Septerna (NASDAQ:SEPN) Shares Up 6.7% Following Analyst Upgrade

Septerna, Inc. (NASDAQ:SEPN) was up 6.7% during mid-day trading on Tuesday after HC Wainwright raised their price target on the stock from $26.00 to $30.00. HC Wainwright currently has a buy rating on the stock. Septerna traded as high as $19.41 and last traded at $19.3150. Approximately 43,161 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 575,080 shares. The stock had previously closed at $18.10.

A number of other equities research analysts have also recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 target price on shares of Septerna in a research note on Friday, September 5th. Wall Street Zen cut shares of Septerna from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.75.

Institutional Investors Weigh In On Septerna

Several institutional investors have recently bought and sold shares of SEPN. Nuveen LLC acquired a new stake in shares of Septerna in the 1st quarter worth approximately $139,000. Checkpoint Capital L.P. bought a new stake in Septerna during the first quarter worth approximately $4,776,000. ADAR1 Capital Management LLC bought a new stake in Septerna during the first quarter worth approximately $4,174,000. BVF Inc. IL lifted its position in Septerna by 79.3% in the first quarter. BVF Inc. IL now owns 4,396,124 shares of the company’s stock worth $25,454,000 after purchasing an additional 1,944,100 shares during the period. Finally, Swiss National Bank bought a new position in Septerna during the 1st quarter valued at $174,000.

Septerna Trading Up 7.7%

The firm has a 50-day moving average price of $18.83 and a 200-day moving average price of $13.48. The company has a market capitalization of $869.31 million and a price-to-earnings ratio of -1.93.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.28). The firm had revenue of $21.50 million for the quarter, compared to the consensus estimate of $24.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. Equities research analysts predict that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.